A20: Understanding the Use and Biology of TNF Therapy in JIA—Clinical Outcomes
Daniel J. Lovell(Cincinnati Children's Hospital Medical Center), Edward H. Giannini(Cincinnati Children's Hospital Medical Center), Sampath Prahalad(Emory University), Michael Shishov(Phoenix Children's Hospital), Anne Johnson(Cincinnati Children's Hospital Medical Center), Dirk Foell(Klinik für Schlafmedizin), Timothy Beukelman(University of Alabama at Birmingham), Bin Huang(Cincinnati Children's Hospital Medical Center), Lawrence Jung(Creighton University), Beth S. Gottlieb, Judyann C. Olson(Medical College of Wisconsin), Kara Schmidt(University of Münster), Paula Morris(Boston Children's Hospital), Karen Onel(Hospital for Special Surgery), Barbara Edelheit(Connecticut Children's Medical Center), Jay Mehta(Sardar Patel University), Murray H. Passo(Cincinnati Children's Hospital Medical Center), Yuki Kimura(Jichi Medical University), Steven J. Spalding(Cleveland Clinic), Elaine Cassidy(Children's Hospital of Pittsburgh)
Cited by 1
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
|The Journal of Immunology|2008|728